Literature DB >> 8726182

Suppository delivery of 5-fluorouracil in rectal cancer.

S Galandiuk1, W Wrightson, L Marr, S Myers, R V LaRocca.   

Abstract

BACKGROUND: Preoperative radiotherapy with concomitant intravenous 5-fluorouracil (5-FU-i.v.) is effective in shrinking locally advanced rectal cancers and facilitating subsequent surgery. Topical 5-FU application may enhance its radiosensitizing and cytotoxic effects. Suppository and intravenous 5-FU administration were compared with respect to myelo-suppression and tissue concentrations.
METHODS: Rats received 120 mg/kg 5-FU-i.v. or via suppository (5-FU-S). White blood cell count, serum albumin, alkaline phosphatase, creatinine, and aspartate aminotransferase (AST) were determined before and serially after 5-FU administration. In a separate experiment, rats received 5-FU-S or 5-FU-i.v. as already described. Portal and systemic blood, rectal, iliac lymph node, liver, and lung tissue were harvested for high-performance liquid chromatography determination of 5-FU concentrations 30 min, 1, 3, 6, and 12 h after drug administration.
RESULTS: No toxicity was observed in 5-FU-S animals, whereas 63% of 5-FU-IV animals had diarrhea. Weight loss and myelosuppression occurred only in 5-FU-i.v. animals. Rectal drug concentrations were significantly higher in the 5-FU-S animals compared with 5-FU-i.v. animals, 0.5-6 h after drug administration. Blood, liver, and lung 5-FU concentrations with 5-FU-S were comparable to those with 5-FU-i.v.
CONCLUSIONS: 5-FU suppositories are associated with fewer systemic side effects and higher rectal 5-FU concentrations than with 5-FU-i.v. administration.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8726182     DOI: 10.1007/BF02306282

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  18 in total

1.  Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity.

Authors:  C R Shumate; T A Rich; J M Skibber; J A Ajani; D M Ota
Journal:  Cancer       Date:  1993-06-01       Impact factor: 6.860

2.  Combined modality preoperative therapy for unresectable rectal cancer.

Authors:  B Percarpio; J Bitterman; K Sabbath; F Alfano; R Ruszkowski; J Bowen
Journal:  Conn Med       Date:  1992-01

3.  A pilot study of protracted venous infusion of 5-fluorouracil and concomitant radiation therapy.

Authors:  T A Rich; J J Lokich; J T Chaffey
Journal:  J Clin Oncol       Date:  1985-03       Impact factor: 44.544

Review 4.  Surgical adjuvant therapy for rectal cancer: present options.

Authors:  J Papillon
Journal:  Dis Colon Rectum       Date:  1994-02       Impact factor: 4.585

5.  Preoperative irradiation and fluorouracil chemotherapy for locally advanced rectosigmoid carcinoma: phase I-II study.

Authors:  J C Landry; M J Koretz; W C Wood; S Bahri; R G Smith; M Costa; G W Daneker; M R York; P R Sarma; M Lynn
Journal:  Radiology       Date:  1993-08       Impact factor: 11.105

6.  Pre-operative combined 5-FU, low dose leucovorin, and sequential radiation therapy for unresectable rectal cancer.

Authors:  B D Minsky; A M Cohen; N Kemeny; W E Enker; D P Kelsen; G Schwartz; L Saltz; J Dougherty; J Frankel; J Wiseberg
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-04-02       Impact factor: 7.038

7.  Distribution and toxicity of 5-fluorouracil after intraperitoneal and anal submucosal administration.

Authors:  M A Mossa; A M Osman; M el-Sayed; A A el-Aaser; N Ismael; M M el-Merzabani
Journal:  J Pharm Belg       Date:  1992 Mar-Apr

8.  Preoperative use of 5-fluorouracil suppository for carcinoma of the rectum.

Authors:  T Takahashi; K Kohno; T Yamaguchi; T Narisawa
Journal:  Am J Surg       Date:  1982-02       Impact factor: 2.565

9.  Effective surgical adjuvant therapy for high-risk rectal carcinoma.

Authors:  J E Krook; C G Moertel; L L Gunderson; H S Wieand; R T Collins; R W Beart; T P Kubista; M A Poon; W C Meyers; J A Mailliard
Journal:  N Engl J Med       Date:  1991-03-14       Impact factor: 91.245

10.  A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid.

Authors:  J H Anderson; D J Kerr; A Setanoians; T G Cooke; C S McArdle
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

View more
  3 in total

Review 1.  Review of Neoadjuvant Chemotherapy Alone in Locally Advanced Rectal Cancer.

Authors:  Omer Jalil; Leica Claydon; Tan Arulampalam
Journal:  J Gastrointest Cancer       Date:  2015-09

2.  Development of in situ gelling and bio adhesive 5-Fluorouracil enema.

Authors:  Lu-Lu Wang; Wen-Sheng Zheng; Shao-Hua Chen; Xia-Qin Fang
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

3.  In situ delivery of thermosensitive gel-mediated 5-fluorouracil microemulsion for the treatment of colorectal cancer.

Authors:  Lu-Lu Wang; Shuai Huang; Hui-Hui Guo; Yan-Xing Han; Wen-Sheng Zheng; Jian-Dong Jiang
Journal:  Drug Des Devel Ther       Date:  2016-09-08       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.